OLOPATADINE HYDROCHLORIDE

Manufacturer
Alembic Pharmaceuticals Inc. | Gland Pharma Limited
Effective date
2019-05-07
Label type
Human Prescription Drug Label
Version
4
Source
full-release
Hydrated at
2026-05-31 20:28:37

Label at a glance#

ProductOLOPATADINE HYDROCHLORIDE
Active ingredientOLOPATADINE HYDROCHLORIDE
Label structure14 sections

Dosage and administration

The recommended dose is one drop in each affected eye once a day.

Storage and handling

Olopatadine hydrochloride ophthalmic solution USP, 0.2% is supplied in a 5 mL screw neck white bottle with nozzle made with low density polyethylene and white color screw cap made with high density polyethylene Tamper evidence is provided with a tamper evident ring around the closure and neck area of the package. 2.5 mL fill in 5 mL bottle (NDC 62332-502-03) Storage Store at 2°C to 25°C (36°F to 77°F)

Label contents#

Full prescribing information#

1 INDICATIONSAND USAGE

INDICATIONS & USAGE SECTION

Olopatadine hydrochloride ophthalmic solution USP, 0.2 % is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose is one drop in each affected eye once a day.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Ophthalmic solution 0.2%: each ml contains 2.22 mg of olopatadine hydrochloride.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 For topical ocular use only.
Not for injection or oral use.

5.2 Contamination of Tip and Solution
As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

5.3 Contact Lens Use
Patients should be advised not to wear a contact lens if their eye is red.

Olopatadine hydrochloride ophthalmic solution USP, 0.2% should not be used to treat contact lens related irritation.

The preservative in Olopatadine hydrochloride ophthalmic solution USP 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling olopatadine hydrochloride ophthalmic solution USP, 0.2% before they insert their contact lenses.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%.


The following adverse experiences have been reported in 5% or less of patients:


Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.


Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.


Some of these events were similar to the underlying disease being studied.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Teratogenic effects: Pregnancy Category C

Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight. There are, however, no adequate and well- controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine hydrochloride ophthalmic solution USP, 0.2% is administered to a nursing mother.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 2 years have not been established.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

11 DESCRIPTION

DESCRIPTION SECTION

Olopatadine hydrochloride ophthalmic solution USP, 0.2% is a sterile ophthalmic solution containing olopatadine for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88 and a molecular formula of C21H23NO3 • HCl.

The chemical structure is presented below:



olopatadine-structure
olopatadine-structure

Chemical Name: 11-[(Z)-3(Dimethylamino) propylidene]-6-11dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride

Each mL of olopatadine hydrochloride ophthalmic solution USP, 0.2% contains: Active: 2.22 mg olopatadine hydrochloride, USP equivalent to 2 mg olopatadine. Inactives: Povidone; Dibasic sodium phosphate; Sodium chloride; Edetate disodium; Benzalkonium chloride 0.01% (preservative); Hydrochloric acid/Sodium hydroxide (adjust pH); and Water for Injection.

It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Olopatadine is a mast cell stabilizer and a histamine H1 antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Systemic bioavailability data upon topical ocular administration of olopatadine hydrochloride ophthalmic solution USP, 0.2% are not available. Following topical ocular administration of olopatadine 0.15% ophthalmic solution in man, olopatadine was shown to have a low systemic exposure.

Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion. Approximately 60 – 70 % of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 μL drop size and a 50 kg person, these doses were approximately 150,000 and 50,000 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of approximately 100,000 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of approximately 15,000 times the MROHD level.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Results from clinical studies of up to 12 weeks duration demonstrate that olopatadine hydrochloride ophthalmic solution USP, 0.2% when dosed once a day is effective in the treatment of ocular itching associated with allergic conjunctivitis.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Olopatadine hydrochloride ophthalmic solution USP, 0.2% is supplied in a 5 mL screw neck white bottle with nozzle made with low density polyethylene and white color screw cap made with high density polyethylene Tamper evidence is provided with a tamper evident ring around the closure and neck area of the package.

2.5 mL fill in 5 mL bottle (NDC 62332-502-03)

Storage

Store at 2°C to 25°C (36°F to 77°F)


17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

17.1 Topical Ophthalmic Use Only
For topical ophthalmic administration only.

17.2 Sterility of Dropper Tip
Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.

17.3 Concomitant Use of Contact Lenses
Patients should be advised not to wear a contact lens if their eyes are red. Patients should be advised that olopatadine hydrochloride ophthalmic solution USP, 0.2% should not be use to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of olopatadine hydrochloride ophthalmic solution USP, 0.2%. The preservative in olopatadine hydrochloride ophthalmic solution, USP benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted following administration

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 62332-502-03
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
Rx only
2.5 mL
Alembic



olopatadine-container
olopatadine-container




NDC 62332-502-03
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
Rx only
2.5 mL
Alembic


olopatadine-carton11
olopatadine-carton11




DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1111343olopatadine HCl 0.2 % Ophthalmic SolutionPSN4
1111343olopatadine 2 MG/ML Ophthalmic SolutionSCD4
1111343olopatadine 0.2 % Ophthalmic SolutionSY4
1111343olopatadine 2 MG/ML (as olopatadine HCl 2.22 MG/ML) Ophthalmic SolutionSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
OLOPATADINE Pharmacologic Class Indexing4Indexing - Pharmacologic Class20220128

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
624001e0-0eba-4aac-a60c-c2ecb37d4f08Product name120220927
abab02bf-82c6-4b6c-8cb4-2ee39055aeb1Product name320210312
ee1438f7-d464-b7de-1b3a-aae378f7d672Product name820200121
4101b788-a943-3f81-6947-4acf7be2af4dProduct name420190703
ca2d4a1a-2b5b-4256-9aad-735e9282b3eeProduct name120150323

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
62332-502-03OLOPATADINE HYDROCHLORIDE2.5 mL in 1 BOTTLE, PLASTICSOLUTION/ DROPS2.54
62332-502-03OLOPATADINE HYDROCHLORIDE1 in 1 CARTONSOLUTION/ DROPS14

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
62332-502OLOPATADINE HYDROCHLORIDE SOLUTION/ DROPS [ALEMBIC PHARMACEUTICALS INC.]4Current NDC, Legacy NDC, 2 package rows20190508_dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
62332-502-03ML - Milliliter62332-50283d91da2-4a23-495e-8bd6-988c0614853312020-01-03

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
62332-50262332-502-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209420-001OLOPATADINE HYDROCHLORIDEOLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29c2088c7a36db…
2026-09-14 22:38:342026-08A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-2984e616aacf4f…
2026-08-18 06:07:402026-07A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-293f01610625f2…
2019-09-15 20:21 UTC2019-09A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICAT2019-04-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A209420-001OLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMIC2019-04-293a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-12-13 00:20 UTC2019-12A209420-001AT174a2ff9319b5…
2020-12-22 03:56 UTC2020-12A209420-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209420-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209420-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A209420-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A209420-001AT1ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OLOPATADINE HYDROCHLORIDEOLOPATADINE HYDROCHLORIDEAlembic Pharmaceuticals Inc.dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d2019-05-07Warnings, Adverse reactionsExact identifier
ndc (package): 62332-502-03
ndc (product): 62332-502
ndc11 (package): 62332050203
spl id: fb3ef8a7-46e3-4d8e-83df-117674d1c8aa
spl set id: dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.